Prophylaxis of peritoneal carcinomatosis in experimental investigations.
OBJECTIVE
We compared the effectiveness and side effects of various cytostatic agents for use in perioperative intraperitoneal irrigation to prevent peritoneal carcinomatosis.


METHODS
The adenocarcinoma cell line CC-531 was implanted during laparotomy at the mesenterial trunk of anesthetized male WAG rats. Direct perioperative intraperitoneal chemotherapy was performed after 5 min with either 5-fluorouracil, cisplatin, or mitomycin; controls received only tumor cells. The animals were inspected daily over 30 days for side effects. They were then killed, and the greater omentum and mesentery were resected, the tumor mass was examined for the presence of peritoneal carcinomatosis, and tumor nodules in the greater omentum and mesentery were counted.


RESULTS
All the animals in the control group developed histologically confirmed peritoneal carcinomatosis. Animals receiving cisplatin or mitomycin by direct intraperitoneal perioperative chemotherapy showed no macroscopic or histological evidence of tumor growth. Two animals in the fluorouracil group had macroscopically and histologically manifest tumor growth; another animal showed only histological evidence of malignancy. Substantial side effects were noted in the cisplatin group, with all animals experiencing bleeding in the peritoneum and toxic necrotic reactions of the colon; two animals died of these side effects.


CONCLUSIONS
Direct intraperitoneal chemotherapy with cisplatin or mitomycin prevents peritoneal carcinomatosis in experimental investigations.
Hribaschek
A
A
Department of Surgery, University of Magdeburg, Germany. arndth@t-online.de
Kuhn
R
R
Pross
M
M
Lippert
H
H
Halangk
W
W
Boltze
C
C
Ridwelski
K
K
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000517:prevention & control; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage* / Q000627:therapeutic use; D007263:Infusions, Parenteral; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D023421:Models, Animal; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D051381:Rats; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil